Pursuant to the Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with Regulation 82(4) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, Solara Active Pharma Sciences has informed that it enclosed the Report of the Monitoring Agency for the quarter ended June 30, 2024, issued by CRISIL Ratings, Monitoring Agency appointed to monitor the utilisation of the proceeds of the Rights Issue of the Company.
The above information is a part of company’s filings submitted to BSE.